ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three... ACR-16 is a dopamine stabilizer.
- Mechanism
- Curator reviewed
ACR16 belongs to a novel class of drugs, characterised as dopaminergic stabilisers, CNS active compounds that can both enhance and counteract dopaminergic effects in the brain depending on the initial level of dopaminergic activity. ARC16 works to "smooth" the many functions of this neurotransmitter chemical in striatum and other areas of the brain. Thus they have the ability to stabilize behavioural and motor disturbances caused by neurological and psychiatric disorders. They do this in pathological states without compromising normal thought processes or motor functions.
- Primary indication
- Investigated for use/treatment in huntington's disease and schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- ACR-16
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with ACR-16, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account